Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | VP - Pharma Operations | October 22, 2018 | October 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date October 22, 2018 · Filed October 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,953 |
Reported balance
After 2018-10-22 transaction · row 1
1 source rowRow 1 · 2018-10-22 · Exercise / conversion · Acquired 13,334 · Balance 45,953 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2019-03-05 | Direct | 0 |
Reported balance
After 2018-10-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-22 · Exercise / conversion · Disposed 13,334 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2018-10-22 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 50,000 F1: On April 28, 2017, Dr. Brodie was granted 50,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.15 · Expires 2021-04-20 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2018-10-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 100,000 F2: On April 20, 2016, Dr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2020-05-04 | Direct | 120,000 |
Reported balance
Holding disclosure · report date 2018-10-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 120,000 F3: On May 4, 2015 Dr, Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 58,000 |
Reported balance
Holding disclosure · report date 2018-10-22 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 58,000 F4: On February 26, 2018, Dr. Brodie was granted 58,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 28, 2017, Dr. Brodie was granted 50,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.
F2: On April 20, 2016, Dr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F3: On May 4, 2015 Dr, Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.
F4: On February 26, 2018, Dr. Brodie was granted 58,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 22, 2018 Filed Oct 24, 2018 22:36 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,334 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001077183-18-000095 · wf-form4_154042059835694.xml · derivative · entry 2 BRODIE STEVEN G. · CIK 0001640522 · VP - Pharma Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,334 shares Expires 2019-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 22:36 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 13,334 | $3.45 | $46,002.30 |
DisclosureSEC source: 0001077183-18-000095 · wf-form4_154042059835694.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · VP - Pharma Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $8.03 Strike: $8.03 | $465,740.00 |
DisclosureSEC source: 0001209191-18-014673 · doc4.xml · derivative · entry 6 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2023-02-26 F5 · derivative.exercise_date: On February 26, 2018, Dr. Brodie was granted 58,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 01:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 6,666 | $3.45 Strike: $3.45 | $22,997.70 |
DisclosureSEC source: 0001209191-17-044259 · doc4.xml · derivative · entry 2 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 6,666 shares Expires 2019-03-05 F1 · derivative.exercise_date: On March 5, 2014, Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date. On July 5, 2017, Dr. Brodie exercised 6,666 options leaving a balance of 13,334. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 01:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,666 | $3.45 | $22,997.70 |
DisclosureSEC source: 0001209191-17-044259 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:55 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $7.52 Strike: $7.52 | $376,000.00 |
DisclosureSEC source: 0001209191-17-029246 · doc4.xml · derivative · entry 5 BRODIE STEVEN G. · CIK 0001640522 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-04-28 F4 · derivative.exercise_date: On April 28, 2017, Dr. Brodie was granted 50,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 21:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option · Derivative | 10,000 | $3.76 Strike: $3.76 | $37,600.00 |
DisclosureSEC source: 0001209191-17-023160 · doc4.xml · derivative · entry 5 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-04-16 Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 21:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherCommon Stock | 10,000 | $3.76 | $37,600.00 |
DisclosureSEC source: 0001209191-17-023160 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,953 Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 33,450 | $7.90 | $264,255.00 |
DisclosureSEC source: 0001209191-17-022294 · doc4.xml · nonDerivative · entry 2 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,953 Read SEC document |
| March 13, 2017 Filed Mar 17, 2017 23:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 16,550 | $8.00 | $132,400.00 |
DisclosureSEC source: 0001209191-17-021567 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,403 Read SEC document |
| March 13, 2017 Filed Mar 22, 2017 20:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 16,550 | $8.00 | $132,400.00 |
DisclosureSEC source: 0001209191-17-022294 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,403 F1 · acquired: This line is included for purposes of amending the filing on 3/17/2017 which inadvertently showed the transaction as securities acquired rather than securities disposed of. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 22:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 10,000 | $1.69 Strike: $1.69 | $16,900.00 |
DisclosureSEC source: 0001209191-16-153941 · doc4.xml · derivative · entry 2 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-04-12 F1 · derivative.exercise_date: On April 12, 2012 Dr.Brodie was granted 10,000 stock options. There was immediate vesting of 2,500 shares and then 2,500 shares will vest on the next three anniversary dates of the grant date. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 22:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 10,000 | $1.69 | $16,900.00 |
DisclosureSEC source: 0001209191-16-153941 · doc4.xml · nonDerivative · entry 1 BRODIE STEVEN G. · CIK 0001640522 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.